Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Accured Expenses: 2009-2025

Historic Change in Accured Expenses for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to -$3.5 million.

  • Gyre Therapeutics' Change in Accured Expenses fell 127.08% to -$3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $654,000, marking a year-over-year increase of 131.25%. This contributed to the annual value of -$1.5 million for FY2024, which is 203.53% down from last year.
  • Per Gyre Therapeutics' latest filing, its Change in Accured Expenses stood at -$3.5 million for Q3 2025, which was down 48.67% from -$2.4 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Change in Accured Expenses ranged from a high of $6.2 million in Q4 2022 and a low of -$5.2 million during Q4 2021.
  • Its 3-year average for Change in Accured Expenses is -$135,000, with a median of -$70,000 in 2024.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 3,441.94% in 2022, then slumped by 3,275.71% in 2025.
  • Over the past 5 years, Gyre Therapeutics' Change in Accured Expenses (Quarterly) stood at -$5.2 million in 2021, then soared by 220.92% to $6.2 million in 2022, then slumped by 76.06% to $1.5 million in 2023, then surged by 39.95% to $2.1 million in 2024, then plummeted by 127.08% to -$3.5 million in 2025.
  • Its Change in Accured Expenses was -$3.5 million in Q3 2025, compared to -$2.4 million in Q2 2025 and $4.4 million in Q1 2025.